AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $94.77, for a total transaction of $168,690.60. Following the sale, the vice president now directly owns 1,780 shares in the company, valued at $168,690.60. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sukumar Nagendran also recently made the following trade(s):

  • On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $101.26, for a total transaction of $180,242.80.
  • On Monday, October 2nd, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00.

AveXis, Inc. (AVXS) traded down $1.53 during trading on Thursday, hitting $91.97. 313,300 shares of the company were exchanged, compared to its average volume of 425,783. AveXis, Inc. has a 52 week low of $44.68 and a 52 week high of $108.27.

AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.04). During the same quarter in the prior year, the business posted ($0.87) EPS. research analysts expect that AveXis, Inc. will post -6.23 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in shares of AveXis during the 3rd quarter valued at $116,000. Botty Investors LLC acquired a new position in shares of AveXis during the 2nd quarter valued at $123,000. Cubist Systematic Strategies LLC lifted its position in shares of AveXis by 688.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after acquiring an additional 1,577 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of AveXis during the 3rd quarter valued at $200,000. Finally, Deschutes Portfolio Strategy LLC acquired a new position in shares of AveXis during the 3rd quarter valued at $203,000. Institutional investors own 92.88% of the company’s stock.

AVXS has been the topic of a number of research reports. BMO Capital Markets reissued a “buy” rating and set a $123.00 target price on shares of AveXis in a report on Friday, August 11th. Bank of America reduced their price objective on shares of AveXis from $115.00 to $112.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $118.00 price objective on shares of AveXis in a research note on Wednesday, August 9th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $134.00 price objective (up from $89.00) on shares of AveXis in a research note on Tuesday, September 5th. Finally, Evercore ISI initiated coverage on shares of AveXis in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $120.00 price objective on the stock. Three analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the stock. AveXis has a consensus rating of “Buy” and an average price target of $110.67.

COPYRIGHT VIOLATION WARNING: “Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/07/sukumar-nagendran-sells-1780-shares-of-avexis-inc-avxs-stock.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.